ResMed Inc. (RMD) — ESG & Values Scores

Environment story

ResMed demonstrates moderate environmental commitment with acknowledged climate risks and emerging disclosure practices, but lacks detailed Scope 3 emissions reporting and net-zero target specificity. The company recognizes climate change as a material business risk and has made some renewable energy investments, but comprehensive supply-chain decarbonization targets remain undisclosed. No major environmental controversies detected, though the 10-K discloses exposure to regulatory and physical climate risks.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Climate Risk Disclosure and Monitoring

10-K Risk Factors section explicitly addresses climate change and natural disasters, including physical risks (extreme weather affecting Sydney and Singapore facilities), regulatory risks (stricter emissions regulations), and transition risks (shifts in customer preference for sustainably produced products).

Enhanced transparency; no quantified emissions reductions documented.
Supply Chain Resilience and Geopolitical Risk Management

Company monitors tariffs, trade restrictions, and geopolitical conflicts (Russia-Ukraine, Iran-Israel, UFLPA Xinjiang restrictions) that could impact supply chains and operational sustainability.

Risk management framework; no direct carbon mitigation claims.

Social story

ResMed maintains reasonably strong social practices with emphasis on employee equity compensation and global workforce. CEO-to-median-worker pay ratio is not disclosed, preventing full assessment under the deterministic 200:1 threshold. No documented union-suppression activities or major labor strikes in past 24 months detected. Leadership diversity composition not explicitly quantified in source documents. Supply-chain ethics are monitored but detailed human-rights audit findings not disclosed. The company settled a 2019 False Claims Act whistleblower case ($40.6M total cost) and operates under Corporate Integrity Agreements through 2027 due to VirtuOx acquisition, indicating historical compliance issues now managed.

Criticisms on file

False Claims Act Settlement (2019) — $40.6M total cost; allegations of providing DME companies free call center services, sleep labs with free/below-cost masks and diagnostic devices, free equipment installation, guaranteed below-market loans, and free home sleep testing devices to non-specialist physicians.
Source: RMD 10-K Risk Factors, Item 1A; settlement agreement with U.S. Department of Justice and U.S. Attorneys' Offices (December 2019).
VirtuOx Corporate Integrity Agreement (2022) — $3.2M civil settlement; allegations from 2016–2020 of False Claims Act violations including misidentification of place of service to obtain higher Medicare reimbursement rates and double-billing for pulse oximetry tests.
Source: RMD 10-K Risk Factors, Item 1A; VirtuOx settlement with OIG (May 11, 2022).

Disclosed initiatives

Broad-Based Employee Stock Purchase Plan (ESPP)

ESPP available to 99% of employees across 33 countries, offering discounted equity participation; 774,618 shares reserved as of June 30, 2025.

Aligns employee and shareholder interests globally; broadens equity ownership.
Executive Compensation Structure with Incentive Alignment

CEO compensation 91% at-risk (STI + LTI); other named executive officers average 81% at-risk. Compensation discussion and analysis disclosed; pay-for-performance methodology documented.

Aligns leadership incentives with long-term shareholder value; transparent compensation governance.
Healthcare Fraud and Abuse Compliance Program

Corporate Integrity Agreements with OIG through 2027 (ResMed agreement through Dec 2024; VirtuOx through 2027). Mandatory compliance monitoring, external audits, and controls on pricing, sales arrangements, and referral source monitoring.

Enforced compliance; mitigates future violations but indicates prior regulatory findings.

Governance story

ResMed exhibits strong governance frameworks with board independence above 75%, transparent director nomination processes, and clear committee structures. No dual-class share structure detected; single-class common stock with standard voting rights. Board composition includes robust tenure balance and skill-set diversity. Lobbying expenditures are not quantified in disclosed documents, preventing precise assessment of environmental-deregulation targeting. Recent antitrust and consumer-safety proceedings are not mentioned; historical False Claims Act settlements indicate past compliance violations now managed through ongoing Corporate Integrity Agreements. Overall governance architecture reflects mature public-company standards.

Criticisms on file

Corporate Integrity Agreement Obligations — ResMed required to implement additional controls on pricing, sales, and referral source monitoring through Dec 2024 (nearing closure); VirtuOx through 2027 including mandatory annual external claims reviews and place-of-service validation.
Source: RMD 10-K Risk Factors, Item 1A; Section on 'We are subject to various risks relating to our compliance with fraud and abuse laws...'

Disclosed initiatives

Board Independence and Committee Structure

11 of 12 director nominees are independent (82% independence). Committees: Audit Committee (Chair: Christopher DelOrefice, independent CFO of BD); Compensation and Leadership Development (Chair: Karen Drexler); Compliance, Privacy and Quality (Chair: Harjit Gill); Nominating and Governance (Chair: Carol Burt). Founder Peter Farrell serves as non-independent director and Chairman Emeritus.

Strong independent oversight; specialized committee governance for audit, compensation, compliance, and director nomination.
Director Nomination and Proxy Access

Nominating and Governance Committee evaluates candidates using diverse skill-set criteria. Proxy access enables eligible stockholders (≥3% ownership for ≥3 years) to nominate up to 20% of board or 2 directors. Tenure balance maintained: 7 of 9 independent directors have ≤10 years tenure; 4 have <5 years.

Transparent, shareholder-friendly director nomination; board renewal without rigid rotation mandates.
Corporate Integrity Agreements and Compliance Oversight

ResMed (CIA through Dec 2024, pending closure) and VirtuOx (CIA through 2027) operate under OIG-mandated compliance programs including annual external audits, claims reviews, and controls on pricing, sales arrangements, and referral source relationships.

Enforced compliance monitoring; reduced material compliance risk post-settlement.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of ResMed Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open ResMed Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)